<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074836</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-51000-20210723-0001</org_study_id>
    <nct_id>NCT05074836</nct_id>
  </id_info>
  <brief_title>Milk Supplementation and Bone Health in Children</brief_title>
  <official_title>Effects of Yili Child Formula Milk on Bone Health in 4-6 Year Children: a 12-month Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: to examine the effects of a Yili child formula milk and regular milk on bone&#xD;
      health and growth in young children.&#xD;
&#xD;
      Study design: cluster randomized controlled trial.&#xD;
&#xD;
      Setting: kindergartens in Hui-ning County of Gansu Province, China (north west).&#xD;
&#xD;
      Participants: &gt;=246 apparent healthy children aged 4-6 years old.&#xD;
&#xD;
      Interventions:&#xD;
&#xD;
      (I) Yili child formula milk (QQ star formula, SCI-PRO NUTR5+6TM), 195 ml *2 /day; (II) Yili&#xD;
      regular milk (pure milk), 195ml*2 /day; (III) Controls: about 50g/d grain foods (containing&#xD;
      20-30 g carbohydrates), e.g. bread.&#xD;
&#xD;
      Interventional Duration: 12 months.&#xD;
&#xD;
      Outcome measures: determined at 0, 6 and 12 months post treatments. Primary outcomes: bone&#xD;
      density and bone mineral contents at the forearm and heel, bone biomarkers.&#xD;
&#xD;
      Secondary outcomes: (1) anthropometric indices: weight, height, waist circumference, etc.;&#xD;
      (2) immune status.&#xD;
&#xD;
      Other measures: dietary intakes, physical activities, general information, medical&#xD;
      information, adverse of side effects.&#xD;
&#xD;
      Data Analyses: The one-year changes and percent changes in the primary and secondary outcomes&#xD;
      will be compared among the 3 groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The two milk products have the same-looking package and similar taste.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline bone mineral density (BMD) at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>BMD (g/cm2) determined by a dual energy x-ray absorptiometry (DXA) at the left forearm and heel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline bone mineral density (BMD) at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>BMD (g/cm2) determined by DXA at the left forearm and heel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline bone mineral contents (BMC) at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>BMC (g) determined by DXA at the left forearm and heel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline bone mineral contents (BMC) at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>BMC (g) determined by DXA at the left forearm and heel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of bone-specific alkaline phosphatase at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Bone turnover marker 1: Bone-specific alkaline phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of bone-specific alkaline phosphatase at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Bone turnover marker 1: Bone-specific alkaline phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of osteocalcin at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Bone turnover marker 2: osteocalcin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of osteocalcin at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Bone turnover marker 2: osteocalcin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of C-terminal telopeptide of type I collagen at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Bone turnover marker 3: C-terminal telopeptide of type I collagen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of C-terminal telopeptide of type I collagen at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Bone turnover marker 3: C-terminal telopeptide of type I collagen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of tartrate resistant acid phosphatase at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Bone turnover marker 4: tartrate resistant acid phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of tartrate resistant acid phosphatase at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Bone turnover marker 4: tartrate resistant acid phosphatase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline body weight at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Anthropometric indices: body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline body height at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Anthropometric indices: body height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline biomarker of body growth at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Biomarker of body growth: insulin-like growth factor 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline immune globulin M (Ig M）at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Immune status: Blood Ig M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline immune globulin G (Ig G）at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Immune status: Blood Ig G</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline immune globulin G (Ig A）at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Immune status: Blood Ig A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline whit blood cell at 12 months</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Immune status: whit blood cell</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Concentrations of blood total 25-hydroxide-vitamin D (25-OH-VD)</measure>
    <time_frame>0, 6 and 12 months</time_frame>
    <description>Serum 25-OH-VD</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentrations of blood parathyroid Hormone (PTH)</measure>
    <time_frame>0, 6 and 12 months</time_frame>
    <description>Serum PTH</description>
  </other_outcome>
  <other_outcome>
    <measure>Nutritional status 1: Body weight</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Body weight (in kg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Nutritional status 2: waist circumference</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Waist circumference (in cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Nutritional status 3: middle-arm circumference</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Middle-arm circumference (in cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Nutritional status 4: skinfold thickness</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Skinfold thickness (in mm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Total consumption of milk and dairy food</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Total consumption of milk and dairy food (in ml/d)</description>
  </other_outcome>
  <other_outcome>
    <measure>Consumption of dietary energy</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Consumption of dietary energy (in kcal/d)</description>
  </other_outcome>
  <other_outcome>
    <measure>Consumption of dietary protein</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Consumption of dietary protein (in g/d)</description>
  </other_outcome>
  <other_outcome>
    <measure>Consumption of dietary calcium</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Consumption of dietary calcium (in mg/d)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Adverse events : assessed by using questionnaires of medical conditions, medications related to milk intake</description>
  </other_outcome>
  <other_outcome>
    <measure>Child behaviors</measure>
    <time_frame>0 and 12 months</time_frame>
    <description>Child behaviours: assessed by using a Child behavior Questionnaire-- parent version. The minimum and maximum values: 26-78; higher scores mean worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>0, 4, 8 and 12 months</time_frame>
    <description>Physical activity (in MET, h/week): assessed by a Child Physical Activity Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentrations of serum calcium</measure>
    <time_frame>0, 6 and 12 months</time_frame>
    <description>Serum calcium (mmol/L)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Bone Density Increased</condition>
  <condition>Body Height</condition>
  <arm_group>
    <arm_group_label>Formula Milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formula milk designed for young children aged over 3 years;&#xD;
Dosage: 195 ml/time;&#xD;
Frequence: 2 times /day;&#xD;
Duration: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular milk (pure milk);&#xD;
Dosage: 195 ml/time;&#xD;
Frequence: 2 times /day;&#xD;
Duration: 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control foods</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Grain foods: e.g., bread;&#xD;
Dosage: 20-40 g/time;&#xD;
Frequence: 2 times /day;&#xD;
Duration: 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Formula milk</intervention_name>
    <description>Brand name: Yili (QQ star formula milk);&#xD;
Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;&#xD;
Dosage: 195ml*2/d;&#xD;
Intervention duration: 12 months</description>
    <arm_group_label>Formula Milk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Regular milk</intervention_name>
    <description>Brand name: Yili；&#xD;
Type: regular milk (pure milk);&#xD;
Dosage: 195ml*2/d;&#xD;
Intervention duration: 12 months</description>
    <arm_group_label>Regular milk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control foods</intervention_name>
    <description>Brand: N/A;&#xD;
Food type: grain foods (e.g., bread);&#xD;
Dosage: 20-40g * 2/d grain foods&#xD;
Intervention duration: 12 months</description>
    <arm_group_label>Control foods</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 4-6 years;&#xD;
&#xD;
          -  female and male&#xD;
&#xD;
          -  Can be enrolled into kindergarten/school as a normal child.&#xD;
&#xD;
          -  Be willing to drinking milk daily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Milk allergy or intolerance, did not to be used to drinking milk;&#xD;
&#xD;
          -  Had the following diseases/conditions confirmed by a hospital: serious diseases of&#xD;
             heart, liver, kidney, brain, hematopoietic system, immunity, thyroid or cancer that&#xD;
             need to be hospitalization for more than 1 week or take medication(s) for more than 1&#xD;
             month with the past two years.&#xD;
&#xD;
          -  having infectious diseases, e.g., tuberculosis, hepatitis, etc.&#xD;
&#xD;
          -  Taking vitamin D, calcium tables or nutrient package;&#xD;
&#xD;
          -  Consumed more than 3 times (&gt;600ml) milk each week in the previous month.&#xD;
&#xD;
          -  Be not willing to provide informed consent, or have other conditions that were&#xD;
             considered to be unsuitable for the study by the investigators.&#xD;
&#xD;
          -  Increases of body health were out of the range between 5-8 cm in the last year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>48 Months</minimum_age>
    <maximum_age>83 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuming Chen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhifu Zhao, M. Phil</last_name>
    <role>Study Chair</role>
    <affiliation>Inner Mongolia Dairy Technology Research Institute Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gangshu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yu-ming Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>milk</keyword>
  <keyword>bone health</keyword>
  <keyword>body growth</keyword>
  <keyword>young children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Published data based on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

